Principia Biopharma Presents Phase 1 Clinical Data from CNS Penetrating BTK Inhibitor Candidate PRN2246/SAR442168 at ACTRIMS 2019
-- Orally administered PRN2246 achieved full BTK occupancy in peripheral blood -- -- PRN2246 exhibited blood-brain barrier permeability and CNS exposure -- -- Sanofi to lead Phase 2 development for people with Multiple Sclerosis -- SOUTH SAN FRANCISCO, …